# Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT00750126** · PHASE2 · UNKNOWN · sponsor: **University Hospital, Clermont-Ferrand** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumors
- Hematologic Neoplasms

## Interventions

- **DRUG:** Fludarabine, Busulfan, Thymoglobulin

## Key facts

- **NCT ID:** NCT00750126
- **Lead sponsor:** University Hospital, Clermont-Ferrand
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-04
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2011-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00750126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00750126, "Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00750126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*